您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > PD 166326
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
PD 166326
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
PD 166326图片
CAS NO:185039-91-2
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
PD 166326 是一种吡啶并嘧啶型受体酪氨酸激酶抑制剂，对 Src 和 Abl 的 IC50 分别为 6 nM 和 8 nM。 PD 166326 具有抗白血病活性。
Cas No.185039-91-2
化学名6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one
Canonical SMILESOCC1=CC=CC(NC2=NC(N(C)C(C(C3=C(Cl)C=CC=C3Cl)=C4)=O)=C4C=N2)=C1
分子式C21H16Cl2N4O2
分子量427.3
溶解度≤25mg/ml in DMSO;25mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 8 nM for c-abl

PD 166326 is a receptor tyrosine kinase inhibitor.

Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. They have been shown not only to be critical regulators of normal cellular processes but also to have a key role in the development of many types of cancer.

In vitro: PD 166326 was identified as a pyridopyrimidine-type inhibitor of receptor tyrosine kinases inhibiting c-abl and Bcr/Abl-dependent cell growth. In addition, PD 166326 could also potently inhibit c-src. Moreover, PD166326 was found to be superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, such as the src family member Lyn [1, 2].

In vivo: In mice with the CML-like disease, PD166326 could rapidly inhibit Bcr/Abl kinase activity after a single po dose and showed great antileukemic activity. It was found that 70% of PD166326-treated mice achieved a white blood cell count less than 20.0 × 109/L at necropsy, compared with 8% of imatinib mesylate–treated animals. Furthermore, 2/3 of PD166326-treated mice had complete resolution of splenomegaly, compared with none of the imatinib mesylate–treated animals. In addition, PD166326 could also prolong the survival of mice with imatinib mesylate–resistant CML induced by the Bcr/Abl mutants of P210/H396P and P210/M351T [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Wisniewski, D. ,Lambek, C.L.,Liu, C., et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Research 62(15), 4244-4255 (2002).
[2] Wolff, N. C.,Veach, D.R.,Tong, W.P., et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105(10), 3995-4003 (2005).